Clinical Trial Update: Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluated first-line therapy with carboplatin and paclitaxel plus TLK286 (Telcyta) in advanced non-small cell lung cancer; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Telcyta (TLK286)

Snippet

Sponsor: Telik | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: COMPLETED